Neumega data

GENIZ (Cambridge, Mass.) announced Phase II results with recombinant human interleukin-11, demonstrating a dose-dependent rise in platelet counts.

Of the

Read the full 203 word article

How to gain access

Continue reading with a
two-week free trial.